By: Megan Campbell, Puget Sound Business Journal
May 12, 2020 - Seattle biotech CEO Shawn Iadonato, who said last year that he wanted to take Kineta public, is keeping a close eye on the market. Iadonato said the biotech still aims to raise crossover funds this year with the goal of doing an initial public offering, but he has not specified a timeline for when that happens.
Financing Led by the Schlaepfer Family Foundation
Seattle, Wash. -- (May 5, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense, announced today that they have successfully closed their most recent funding round totaling $5 million. This round was led by the Bellevue-based Schlaepfer Family Foundation.
The Schlaepfer Family Foundation honors individuals and organizations based on three guiding principles: freedom, service and civil liberty
Bellevue, Wash. -- (February 25, 2020) Phil Schlaepfer and his family launched a new philanthropic foundation today, the Schlaepfer Family Foundation. The foundation is rooted in a deep commitment to honoring service and sacrifice and advancing opportunities for individuals and families who are committed to self-improvement.